Results 21 to 30 of about 96,303 (248)

Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study

Vaccines, 2022
Background: Several countries are implementing COVID-19 booster vaccination campaigns. The objective of this study was to model the impact of different primary and booster vaccination strategies.
Clément R. Massonnaud, Jonathan Roux, Vittoria Colizza, Pascal Crépey   +3 more
doaj   +1 more source

COVID Arm After Moderna Booster in Healthcare Worker: A Case Report

Acta Medica Indonesiana, 2021
SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate
Anshari Saifuddin, Sukamto Koesnoe, Nia Kurniati, Sondang Sirait, Riesye Arisanty, Evy Yunihastuti   +5 more
doaj  

Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers

Frontiers in Immunology, 2022
Data on humoral and cellular responses to BNT162b2 as a booster dose, following two doses of ChAdOx1 nCov-19 vaccine, have seldom been reported. The aim of this study was to assess the positivity rates of three representative antibody assays targeting ...
Seri Jeong, Nuri Lee, Su Kyung Lee, Eun-Jung Cho, Jungwon Hyun, Min-Jeong Park, Wonkeun Song, Hyun Soo Kim   +7 more
doaj   +1 more source

Article Hedges vs boosters: Communicative mitigation and enhancement in the genre of dissertation review [PDF]

Жанры речи, 2023
The article presents the results of the cross-disciplinary research which focuses on the two types of discourse markers – hedges and boosters and their use in Russian official dissertation reviews.
Viktorova, Elena Yurievna
doaj   +1 more source

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant

MedComm, 2022
The SARS‐CoV‐2 Omicron BA.1 variant of concern contains more than 30 mutations in the spike protein, with half of these mutations localized in the receptor‐binding domain (RBD).
Zhongcheng Zhou, Peng Du, Ning Li, Xinxin Xiong, Shengjun Tang, Qinjin Dai, Taorui Wang, Meixing Yu, Miao Man, Kelvin Lam, Daniel T. Baptista‐Hon, Wa Hou Tai, Olivia Monteiro, Weng Sam Ng, Un Man Lee, Zhihai Liu, Kang Zhang, Gen Li   +17 more
doaj   +1 more source

COVID-19 Booster Vaccine Hesitancy among Hemodialysis Patients in Saudi Arabia Using the Health Belief Model: A Multi-Centre Experience

Vaccines, 2022
Objective: Vaccination hesitance for the COVID-19 booster dosage among hemodialysis patients is an important barrier in reducing morbidity and mortality linked to COVID-19 infection. Hence, this study aimed to explore the predictors of the third (booster)
Sami Alobaidi, Enad Alsolami, Abdalla Sherif, Mohammed Almahdy, Rady Elmonier, Waad Y. Alobaidi, Ahmed Akl   +6 more
doaj   +1 more source

Insights from Team Clinic: A Person-Centered Virtual Peer Group Care Model Adapted for Marginalized and Historically Excluded Youth with Type 1 Diabetes (T1D)

Children
Background: Despite advancements in T1D care regimens, racially and ethnically diverse youth with low income continue to experience worse health outcomes, more psychosocial challenges, and higher barriers to care.
Jaquelin Flores Garcia, Mark W. Reid, Alejandra Torres Sanchez, Valerie Ruelas, Sarah-Jeanne Salvy, Alex Thomas, Gary Ashwal, D. Steven Fox, Jennifer K. Raymond   +8 more
doaj   +1 more source

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis

Clinical Case Reports, 2022
We described a rare case of vaccine‐induced acalculous cholecystitis (ACC). A 52‐year‐old female developed ACC after 8 h of receiving a 3rd dose of the Pfizer‐BioNTech COVID‐19 vaccination. The symptoms subsided completely with conservative treatment for
Bianca Maria Wahlen, Ruben Peralta, Hassan Al‐Thani, Ayman El‐Menyar   +3 more
doaj   +1 more source

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Vaccines
Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of an ongoing, open-label, phase 2/3 study of monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg dose).
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin   +20 more
doaj   +1 more source

Communication and Language Profiles of Children Treated for Posterior Fossa Brain Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cognitive and language deficits are frequently reported sequelae of posterior fossa brain tumors (PFBT). Typically, delayed onset impedes prompt assessment and early intervention. This has devastating implications for quality of life.
Zara Sved, Meghan Hesse, Jennie Cusiter, Annabel Webb, Kimberley Docking   +4 more
wiley   +1 more source